



## **Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry**

Marc Patterson, Eugen Mengel, Frits Wijburg, Audrey Muller, Barbara Schwierin, Harir Drevon, Marie Vanier, Mercé Pineda

### **► To cite this version:**

Marc Patterson, Eugen Mengel, Frits Wijburg, Audrey Muller, Barbara Schwierin, et al.. Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet Journal of Rare Diseases, 2013, 8 (1), pp.73. inserm-00823374

**HAL Id: inserm-00823374**

**<https://inserm.hal.science/inserm-00823374>**

Submitted on 16 May 2013

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**CORRECTION**

**Open Access**

# Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry

Marc C Patterson<sup>1,8\*</sup>, Eugen Mengel<sup>2</sup>, Frits A Wijburg<sup>3</sup>, Audrey Muller<sup>4</sup>, Barbara Schwierin<sup>4</sup>, Harir Drevon<sup>5</sup>, Marie T Vanier<sup>6</sup> and Mercé Pineda<sup>7</sup>

## Correction

After the publication of this work [1] it was brought to the authors attention that Figure 1 contained an inversion in the color of the triangles, where yellow which should be "diagnosis" is said to be "first miglustat use", and blue which should be "first miglustat use" is said to be "diagnosis". The correct figure is given below:

## Author details

<sup>1</sup>Mayo Clinic, Rochester, MN, USA. <sup>2</sup>Villa Metabolica, ZKJM, MC, University of Mainz, Mainz, Germany. <sup>3</sup>Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. <sup>4</sup>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. <sup>5</sup>Numerus Ltd, Wokingham, UK. <sup>6</sup>INSERM Unit 820, Lyon, France. <sup>7</sup>Fundació Hospital Sant Joan de Déu, Barcelona, Spain. <sup>8</sup>Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Received: 7 May 2013 Accepted: 7 May 2013

Published: 14 May 2013

## References:

1. Patterson MC, Eugen M, Wijburg FA, Audrey M, Barbara S, Harir D, Vanier MT, Mercé P: **Disease and patient characteristics in NP-C patients: findings from an international disease registry.** *Orphanet Journal of Rare Diseases* 2013, **8**:12.

doi:10.1186/1750-1172-8-73

**Cite this article as:** Patterson et al.: Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry. *Orphanet Journal of Rare Diseases* 2013 **8**:73.

\* Correspondence: [patterson.marc@mayo.edu](mailto:patterson.marc@mayo.edu)

<sup>1</sup>Mayo Clinic, Rochester, MN, USA

<sup>8</sup>Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA


Full list of author information is available at the end of the article

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)





**Figure 1** Overview of patient and disease characteristics. We regret any inconvenience that this inaccuracy may have caused.